CLINICAL TRIALS PROFILE FOR IOBENGUANE I-131

All Clinical Trials for iobenguane i-131

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00126412 ↗	Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma	Completed	GE Healthcare	Phase 3	2005-08-02	The study is designed to study the effectiveness of 123I-mIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroblastoma or phaeochromocytoma.
NCT00126425 ↗	Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease	Completed	GE Healthcare	Phase 3	2005-07-01	The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcomes in subjects with heart failure and in comparison to subjects without cardiovascular disease.
NCT00126438 ↗	Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease	Completed	GE Healthcare	Phase 3	2005-07-01	The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcome in subjects with heart failure and in comparison to subjects without cardiovascular disease.
NCT00339131 ↗	ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid	Completed	Molecular Insight Pharmaceuticals, Inc.	Phase 1	2006-06-01	The purpose of this study is to test the safety of a drug called Ultratrace iobenguane I 131 that has radioactivity, to measure how long it takes for the drug to be absorbed and passed out of the body, and to measure how much radioactivity is absorbed into different tissues of the body.
NCT00458952 ↗	Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma	Completed	Molecular Insight Pharmaceuticals, Inc.	Phase 1/Phase 2	2007-04-01	The purpose of this study is to determine whether iobenguane I 131 is safe and effective in patients with malignant pheochromocytoma or paraganglioma.
NCT00659984 ↗	N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma	Completed	Molecular Insight Pharmaceuticals, Inc.	Phase 2	2008-06-01	RATIONALE: Radioactive drugs, such as iodine I 131 metaiodobenzylguanidine (MIBG), may carry radiation directly to tumor cells and not harm normal cells. A bone marrow or peripheral stem cell transplant using stem cells from the patient may be able to replace blood-forming cells that were destroyed by I 131 MIBG. PURPOSE: This phase II trial is studying the side effects and best dose of iodine I 131 MIBG followed by a stem cell transplant in treating young patients with relapsed or refractory high-risk neuroblastoma.
NCT00730444 ↗	Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma	Approved for marketing	GE Healthcare		1969-12-31	GE Healthcare has recently submitted a New Drug Application (NDA) for Iobenguane I 123 Injection ([123I]mIBG (AdreView)) as a diagnostic nuclear imaging agent for the detection of primary or metastatic neuroblastoma and pheochromocytoma. The present protocol establishes an Expanded Access program to provide AdreView to pediatric medical centers and hospitals that treat neuroblastoma patients. AdreView will be provided for use in diagnostic assessment of patients with known or suspected neuroblastoma for whom there is an appropriate clinical indication for [123I]mIBG imaging.

Clinical Trial Conditions for iobenguane i-131

Condition Name

Condition Name for iobenguane i-131
Intervention	Trials
Neuroblastoma	7
Pheochromocytoma	4
Ganglioneuroblastoma	3
Paraganglioma	3

Condition MeSH

Condition MeSH for iobenguane i-131
Intervention	Trials
Neuroblastoma	9
Heart Failure	4
Pheochromocytoma	4
Paraganglioma	3

Clinical Trial Locations for iobenguane i-131

Trials by Country

Trials by Country for iobenguane i-131
Location	Trials
United States	120
Canada	6
Puerto Rico	1

Trials by US State

Trials by US State for iobenguane i-131
Location	Trials
Texas	7
Pennsylvania	7
North Carolina	7
Ohio	6
Illinois	6

Clinical Trial Progress for iobenguane i-131

Clinical Trial Phase

Clinical Trial Phase for iobenguane i-131
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	4
Phase 2	3

Clinical Trial Status

Clinical Trial Status for iobenguane i-131
Clinical Trial Phase	Trials
Completed	9
Recruiting	3
Approved for marketing	2

Clinical Trial Sponsors for iobenguane i-131

Sponsor Name

Sponsor Name for iobenguane i-131
Sponsor	Trials
Molecular Insight Pharmaceuticals, Inc.	5
National Cancer Institute (NCI)	5
GE Healthcare	5

Sponsor Type

Sponsor Type for iobenguane i-131
Sponsor	Trials
Industry	13
Other	6
NIH	5

Clinical Trials Update, Market Analysis, and Projection for Iobenguane I-131

Last updated: October 31, 2025

---

Introduction

Iobenguane I-131, also known as Azedra, is a radiopharmaceutical primarily used for targeted radiotherapy of certain neuroendocrine tumors, particularly pheochromocytomas and paragangliomas. Its unique mechanism involves delivering targeted radiation to tumor cells expressing norepinephrine transporters, thereby minimizing systemic toxicity. As the demand for precision oncology accelerates, understanding the clinical development, market dynamics, and future outlook of Iobenguane I-131 is crucial for stakeholders across healthcare, biotech, and investment sectors.

Clinical Trials Update

Regulatory History and Current Status

Iobenguane I-131 received FDA approval in 2018 for the treatment of adult patients with confirmed, locally advanced, or metastatic pheochromocytoma or paraganglioma (PPGL) that cannot be surgically resected. The approval was based on pivotal data from the Phase 3 Study (ZX001-201), which demonstrated significant objective response rates and manageable safety profiles.

Since approval, the drug has been incorporated into clinical guidelines, notably the NCCN guidelines for neuroendocrine tumors, bolstering its clinical adoption. The primary ongoing clinical activity focuses on expanding its application spectrum and optimizing dosing protocols.

Ongoing and Upcoming Trials

1. Extended Indications:

   • Trials evaluating Iobenguane I-131 in combination with other targeted agents or immunotherapy for broader neuroendocrine tumor types are underway. For example, a Phase 2 study currently recruiting patients aims to assess efficacy in patients with metastatic carcinoid tumors.
   • A clinical trial initiated in 2022 (ClinicalTrials.gov NCT05180823) is examining the use of Iobenguane I-131 in pediatric populations with neuroblastoma, an application compatible with its mechanism, though regulatory approval is pending.

2. Dosing and Safety Optimization:

   • Studies investigating dose escalation and fractionated dosing schedules to enhance therapeutic outcomes without increasing toxicity are ongoing, including international multicenter trials.

3. Imaging and Diagnostic Applications:

   • Iobenguane scans (meta-iodobenzylguanidine imaging) complement its therapeutic use, enhancing tumor detection fidelity. Research exploring quantitative imaging biomarkers aims to refine patient selection and response monitoring.

Clinical Challenges

While effective, Iobenguane I-131's use is limited by potential hematopoietic toxicity, necessity for specialized handling, and regulatory hurdles for new indications. The expansion into combination therapies and pediatric applications could overcome current treatment limitations.

Market Analysis

Market Size and Growth Drivers

The global market for neuroendocrine tumor treatments, including radiopharmaceuticals, is expanding rapidly. According to Grand View Research, the neuroendocrine tumor therapeutics market was valued at approximately USD 1.3 billion in 2021, with an expected CAGR exceeding 9% through 2030.

Iobenguane I-131 is projected to capture a significant share owing to:

• Its FDA-approval and strong clinical efficacy data.
• Regulatory endorsements and incorporation into guidelines.
• Growing diagnosis rates for neuroendocrine tumors, driven by increased awareness and advanced imaging.

Regional Market Dynamics

• United States: Dominates due to early approval, established healthcare infrastructure, and active clinical adoption.
• Europe: Growing use facilitated by EMA approvals and national guidelines.
• Asia-Pacific: Expanding market driven by research investments and rising healthcare spending. However, regulatory pathways are still evolving.

Competitive Landscape

Iobenguane I-131’s main competitors include other peptide receptor radionuclide therapies like Lutetium-177 DOTATATE (Lutathera). While Lutathera is approved for gastroenteropancreatic neuroendocrine tumors, Iobenguane I-131 remains uniquely positioned for non-gastrointestinal neuroendocrine tumors like pheochromocytomas.

Emerging radiopharmaceuticals and targeted therapies, such as alpha-emitting agents, might pose future competition but are currently in early stages of development.

Market Challenges

• Regulatory: Approval processes for new indications or pediatric uses.
• Manufacturing: Complexity of radiopharmaceutical production limits global availability.
• Reimbursement: High upfront costs and specialized administration requirements affect coverage.

Market Projection (2023-2030)

Based on current clinical and regulatory momentum, combined with rising diagnosis and treatment rates, the Iobenguane I-131 market is expected to grow at a CAGR of 8-10% over the next decade. The projected compound annual growth rate (CAGR) underscores its potential to reach USD 2.1-2.5 billion by 2030, predominantly driven by:

• Expanded indications, including pediatric neuroblastoma.
• Combination therapy trials improving efficacy.
• Increased clinician familiarity and acceptance.

Future Outlook

The future of Iobenguane I-131 hinges on clinical trial success, regulatory advancements, and healthcare integration. Key areas to watch include:

• Validation of new indications in neuroendocrine and pediatric tumors.
• Technological innovations in radiolabeling and delivery.
• Expanding global access through manufacturing scalability and reimbursement strategies.

Partnerships between biotech firms, academic institutions, and regulatory agencies will be pivotal to overcoming clinical and logistical hurdles.

---

Key Takeaways

• Iobenguane I-131’s approval for pheochromocytoma and paraganglioma solidifies its role in targeted radiotherapy for neuroendocrine tumors.
• Ongoing trials targeting additional neuroendocrine tumor types and pediatric applications could substantially expand its market.
• The global neuroendocrine tumor therapeutics market is poised for robust growth, with Iobenguane I-131 positioned as a key player.
• Market expansion depends on regulatory approvals, manufacturing capabilities, and reimbursement policies.
• Collaboration, innovation, and clinical validation will drive the future growth trajectory of Iobenguane I-131.

---

FAQs

1. What distinguishes Iobenguane I-131 from other radiopharmaceuticals?
Its selective uptake by neuroendocrine tumor cells expressing norepinephrine transporters allows for targeted radiation, minimizing damage to surrounding tissues. This specificity makes it uniquely suitable for certain tumors like pheochromocytomas.

2. Are there ongoing efforts to expand Iobenguane I-131’s indications?
Yes, multiple clinical trials are assessing its efficacy in neuroblastoma, metastatic carcinoid tumors, and combinations with immunotherapies, broadening its potential therapeutic scope.

3. What are the primary safety concerns associated with Iobenguane I-131?
Hematopoietic toxicity, including bone marrow suppression, remains a key concern. Proper patient selection and supportive care are essential to managing risks.

4. How does the competitive landscape impact Iobenguane I-131’s market?
While therapies like Lutetium-177 DOTATATE target different tumor types, Iobenguane I-131’s unique indication niche grants it a differentiated position. Competition may intensify as novel radiopharmaceuticals gain approval.

5. What are the barriers to global adoption of Iobenguane I-131?
Manufacturing complexity, regulatory differences, high costs, and need for specialized handling facilities restrict widespread access, especially in low- and middle-income countries.

---

References

1. U.S. Food and Drug Administration. FDA approves drug to treat rare tumors. (2018).
2. Grand View Research. Neuroendocrine Tumors Market Analysis. 2022.
3. ClinicalTrials.gov. Ongoing clinical studies involving Iobenguane I-131.
4. NCCN Guidelines. Neuroendocrine Tumors. 2022.